An open study of @entity2044 in the treatment of XXXX -dependent @entity565 .

@entity1 @entity1223 @entity565 @entity229 @entity5132 @entity134 @entity112 @entity116 @entity2710 @entity2044
To determine the efficacy of oral gold in @entity565 , 20 @entity1 with @entity134 -dependent @entity565 received @entity2044 at a dose of 3 mg by mouth, twice daily, in a 24-week open clinical trial. Prospective evaluation of bronchial responsiveness to @entity2710 was determined before and 8 and 16 weeks after initiation of @entity2044 therapy. Serial spirometry (FEV1 and FVC), lung volumes, and diffusing capacities (single breath @entity1223 diffusing capacity of the lungs) were measured before and at 10 and 20 weeks after treatment. All subjects were required to record concomitant medications, symptom scores, and morning and evening peak expiratory flow rates. In vitro immunologic studies performed before and after 8 and 20 weeks of @entity2044 therapy included leukocyte @entity112 release in response to antihuman IgE, lymphocyte blast transformation in response to concanavalin A and phytohemagglutinin, and leukocyte inhibitory factor activity in response to @entity5132 and @entity116 toxoid antigens. In 18 @entity1 evaluated, there were no significant differences between baseline and posttreatment spirometry, single breath @entity1223 diffusing capacity of the lungs, and lung volumes. At week 16 of treatment, the @entity134 cumulative dose or the total @entity229 dose administered from 7 days before through 10 days after each @entity2710 test day decreased from a mean of 293 +/- 125 mg at baseline to 192 +/- 115 mg. At week 16, nine of 18 @entity1 (50%) exhibited decreased @entity2710 responsiveness as defined by a more than one-half log10 increase in the concentration of @entity2710 causing a 20% decrease in FEV1. A significant correlation (r = 0.60) was observed between the increase in the concentration of @entity2710 causing a 20% decrease in FEV1 and the decrease in @entity134 cumulative dose after 16 weeks of treatment. Leukocyte @entity112 release to anti-IgE exhibited significant reductions from baseline at week 20 to 10(-2) (p less than 0.002) and at 10(-3) (p less than 0.005) dilutions. At week 20, leukocyte inhibitory factor activity in response to Candida increased from baseline at the 0.1 mg per well (p = 0.025) and 1 mg per well (p = 0.05) concentrations; similarly, the responses to @entity116 toxoid increased at the 1 mg per well (p less than 0.05) and 0.1 mg per well (p less than 0.01) concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)
